VJTBio Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
200
- Latest Deal Type
-
Later Stage VC
- Investors
-
11
VJTBio General Information
Description
Developer of biopharmaceuticals for the purpose of reproductive and immune health. The company's biopharmaceuticals are developed using genetic recombination, with a focus on animal reproduction, disease prevention and pet health, providing the biopharmaceutical industry and medical professionals with clinical testing and technical services.
Contact Information
Website
www.vjtbio.comCorporate Office
- Building 2, No. 9 Yongteng North Road, Yongfeng Base
- Haidian District
- Beijing, 100085
- China
Corporate Office
- Building 2, No. 9 Yongteng North Road, Yongfeng Base
- Haidian District
- Beijing, 100085
- China
VJTBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 19-Sep-2023 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series C) | 29-Mar-2023 | Completed | Generating Revenue | |||
| 3. Later Stage VC | 02-Jun-2021 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 30-Oct-2020 | $14.8M | $14.8M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 17-Sep-2019 | Completed | Generating Revenue |
VJTBio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
VJTBio Patents
VJTBio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026145790-A1 | Pharmaceutical combination for improving reproductive and production performance of dam | Pending | 06-Jan-2025 | ||
| WO-2025252263-A1 | Recombinant fish gth fusion protein, preparation method therefor, and use thereof | Pending | 03-Jun-2024 | ||
| WO-2025237320-A1 | Recombinant porcine interferon λ1 fusion protein, preparation method therefor and use thereof | Pending | 14-May-2024 | ||
| AU-2024396711-A1 | Anti-canine pd-1 antibody and use thereof | Pending | 06-Dec-2023 | ||
| EP-4821946-A1 | Anti-canine pd-1 antibody and use thereof | Pending | 06-Dec-2023 | C07K16/2818 |
VJTBio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
VJTBio Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Hoshi Capital | Venture Capital | Minority | ||
| Capital Development Investment Fund (China) | Venture Capital | Minority | ||
| China Life Private Equity | PE/Buyout | Minority | ||
| Shanghai STVC Group | Growth/Expansion | Minority | ||
| Wuxi Taihu New City Development Group | Corporation | Minority |
VJTBio FAQs
-
When was VJTBio founded?
VJTBio was founded in 2016.
-
Where is VJTBio headquartered?
VJTBio is headquartered in Beijing, China.
-
What is the size of VJTBio?
VJTBio has 200 total employees.
-
What industry is VJTBio in?
VJTBio’s primary industry is Biotechnology.
-
Is VJTBio a private or public company?
VJTBio is a Private company.
-
What is VJTBio’s current revenue?
The current revenue for VJTBio is .
-
How much funding has VJTBio raised over time?
VJTBio has raised $14.8M.
-
Who are VJTBio’s investors?
Hoshi Capital, Capital Development Investment Fund (China), China Life Private Equity, Shanghai STVC Group, and Wuxi Taihu New City Development Group are 5 of 11 investors who have invested in VJTBio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
